Sector News

Merck adds to lung cancer wall with Otsuka deal

January 6, 2020
Life sciences

Merck isn’t placing all of its oncology bets on Keytruda (pembrolizmab). Last month, the pharma showed how much interest it had in targeted drugs called kinase inhibitors when it spent $2.7 billion to snatch up ArQule.

Today’s announcement of a $50 million collaboration with Astex and Taiho represents a much smaller ante. The collaboration covers preclinical research on small molecule agents targeting cancer-related mutations being conducted by all three companies. This includes the KRAS oncogene, once thought to be an undruggable target.

Interest in inhibiting KRAS has heightened over the past year as Amgen has revealed data from its leading candidate, called AMG 510, which is now in Phase 1/2 study along with Mirati’s MRTX849. Eli Lilly and J&J have initiated early trials of their drugs LY3499446 and JNJ-74699157​, respectively.

Merck’s interest in KRAS inhibition is a sign that it believes its biological agent Keytruda, which was on track to hit $11 billion in sales in 2019, could be vulnerable to competition in diseases like lung cancer.

Last month, it released exploratory data from the KEYNOTE-042 trial indicating that in previously untreated patients with non-squamous non-small cell lung cancer (NSCLC) that expresses Keytruda’s target, called PD-1, the immuno-oncology drug alone was able to shrink tumors and delay death or disease progression in KRAS-positive patients better than chemotherapy. The finding prompted Cantor Fitzgerald analyst Louise Chen to say KRAS could “fade like a fad” if the data is confirmed in additional clinical study.

Merck doesn’t seem to think it can ignore targeted KRAS agents, however. Having its own KRAS-targeting drug could serve to secure its leading place in lung cancer, where AMG 510 and MRTX849 have been able to shrink or eliminate tumors in patients.

In Astex, the New Jersey-based big pharma found a partner that has already had some discovery success. Its research led to the successful launch of Novartis’ breast cancer drug Kisqali (ribociclib) and Johnson & Johnson’s urothelial cancer drug Balversa (erdafitinib).

By Jonathan Gardner

Source: Biopharma Dive

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend